Table 1.
Stage-dependent alterations in cancer cell metabolism.
| Cause | Effect | Potential treatment | |
|---|---|---|---|
| Intrinsic (Warburg) | P53-deficient tumor cells do not have functional SCO2 or TIGAR and display a glycolytic metabolism phenotype | Protect from apoptosis by closing Kv channels and preventing the influx of calcium | Dichloroacetate, lonidamine |
| Embryonic M2 isoform of pyruvate kinase shifts cellular metabolism to aerobic glycolysis | Satisfaction of anabolic requirements, biosynthetic activities by proliferating tumor cells entail the production of ribose-5-phosphate for nucleotide biosynthesis, and the production of fatty acids for lipid biosynthesis | ||
| Deadhesion | Deadherent cells suffer deficit in glucose transport, resulting in adenosine triphosphate (ATP) deficiency and anoikis | Peroxide signaling, increased mitochondrial activity | Anti-oxidants |
| Serine–glycine–creatine pathway regenerates ATP | |||
| Stromal interaction | Lactate secretion from mesenchymal cells via the transporter MCT4 | Tumor cells import this lactate via MCT1 expression, converting it to pyruvate and introducing it into the Krebs cycle, resulting increased in oxidative phosphorylation and ATP production | |
| Hypoxia | Hypoxia, low-glucose, lactate | Induction of HIF-1, carbonic anhydrase IX | Methazolamide |